Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
NCT ID: NCT04697160
Last Updated: 2021-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3573 participants
OBSERVATIONAL
2020-04-01
2021-05-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who received systemic therapies for R/R DLBCL
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Non-Eligibility Criteria:
1. Patients with central nervous system (CNS) involvement by lymphoma at initial DLBCL diagnosis.
2. Patients who were treated with CD19-targeted therapy or immunomodulatory drugs (IMiDs) (e.g., thalidomide, LEN) as a frontline DLBCL therapy.
3. Patients who underwent an allogeneic stem cell transplant.
4. Patients who had a prior history of malignancies other than DLBCL, unless the patient has been free of the disease for ≥5 years prior to inclusion.
Note: Patients with the following malignancies within the 5 years period are still eligible:
1. basal cell carcinoma of the skin
2. squamous cell carcinoma of the skin
3. carcinoma in situ of the cervix
4. carcinoma in situ of the breast
5. carcinoma in situ of the bladder
6. incidental histological finding of prostate cancer (Tumor/Node/Metastasis \[TNM\] stage of T1a or T1b)
5. Patients who received tafasitamab.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MorphoSys AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva Waltl
Role: STUDY_DIRECTOR
MorphoSys AG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MorphoSys Research Site
Scottsdale, Arizona, United States
MorphoSys Research Site
Clovis, California, United States
MorphoSys Research Site
Los Angeles, California, United States
MorphoSys Research Site
Orange, California, United States
MorphoSys Research Site
Torrance, California, United States
MorphoSys Research Site
Broomfield, Colorado, United States
MorphoSys Research Site
Chicago, Illinois, United States
MorphoSys Research Site
Skokie, Illinois, United States
MorphoSys Research Site
Indianapolis, Indiana, United States
MorphoSys Research Site
Wichita, Kansas, United States
MorphoSys Research Site
Ann Arbor, Michigan, United States
MorphoSys Research Site
Minneapolis, Minnesota, United States
MorphoSys Research Site
Rochester, Minnesota, United States
MorphoSys Research Site
Jackson, Mississippi, United States
MorphoSys Research Site
Morristown, New Jersey, United States
MorphoSys Research Site
New York, New York, United States
MorphoSys Research Site
New York, New York, United States
MorphoSys Research Site
Charlotte, North Carolina, United States
MorphoSys Research Site
Portland, Oregon, United States
MorphoSys Research Site
Nashville, Tennessee, United States
MorphoSys Research Site
Salt Lake City, Utah, United States
MorphoSys Research Site
Spokane, Washington, United States
MorphoSys Research Site
Adelaide, , Australia
MorphoSys Research Site
Benowa, , Australia
MorphoSys Research Site
Concord, , Australia
MorphoSys Research Site
Darlinghurst, , Australia
MorphoSys Research Site
East Melbourne, , Australia
MorphoSys Research Site
Fitzroy, , Australia
MorphoSys Research Site
Frankston, , Australia
MorphoSys Research Site
Kingswood, , Australia
MorphoSys Research Site
Nedlands, , Australia
MorphoSys Research Site
Leoben, , Austria
MorphoSys Research Site
Linz, , Austria
MorphoSys Research Site
Salzburg, , Austria
MorphoSys Research Site
Sankt Pölten, , Austria
MorphoSys Research Site
Vienna, , Austria
MorphoSys Research Site
Wels, , Austria
MorphoSys Research Site
Edmonton, , Canada
MorphoSys Research Site
Montreal, , Canada
MorphoSys Research Site
Aalborg, , Denmark
MorphoSys Research Site
Albi, , France
MorphoSys Research Site
Amiens, , France
MorphoSys Research Site
Angers, , France
MorphoSys Research Site
Caen, , France
MorphoSys Research Site
Carcassonne, , France
MorphoSys Research Site
Castres, , France
MorphoSys Research Site
Chambéry, , France
MorphoSys Research Site
Grenoble, , France
MorphoSys Research Site
La Roche-sur-Yon, , France
MorphoSys Research Site
Lille, , France
MorphoSys Research Site
Montpellier, , France
MorphoSys Research Site
Narbonne, , France
MorphoSys Research Site
Nice, , France
MorphoSys Research Site
Nîmes, , France
MorphoSys Research Site
Orléans, , France
MorphoSys Research Site
Paris, , France
MorphoSys Research Site
Paris, , France
MorphoSys Research Site
Perpignan, , France
MorphoSys Research Site
Pessac, , France
MorphoSys Research Site
Pierre-Bénite, , France
MorphoSys Research Site
Quimper, , France
MorphoSys Research Site
Rodez, , France
MorphoSys Research Site
Rouen, , France
MorphoSys Research Site
Saint-Brieuc, , France
MorphoSys Research Site
Saint-Priest-en-Jarez, , France
MorphoSys Research Site
Saint-Quentin, , France
MorphoSys Research Site
Toulouse, , France
MorphoSys Research Site
Tours, , France
MorphoSys Research Site
Troyes, , France
MorphoSys Research Site
Vandœuvre-lès-Nancy, , France
MorphoSys Research Site
Aschaffenburg, , Germany
MorphoSys Research Site
Augsburg, , Germany
MorphoSys Research Site
Bad Liebenwerda, , Germany
MorphoSys Research Site
Cologne, , Germany
MorphoSys Research Site
Donauwörth, , Germany
MorphoSys Research Site
Dresden, , Germany
MorphoSys Research Site
Dresden, , Germany
MorphoSys Research Site
Flensburg, , Germany
MorphoSys Research Site
Frechen, , Germany
MorphoSys Research Site
Freiburg im Breisgau, , Germany
MorphoSys Research Site
Göttingen, , Germany
MorphoSys Research Site
Halle, , Germany
MorphoSys Research Site
Hamburg, , Germany
MorphoSys Research Site
Hanover, , Germany
MorphoSys Research Site
Hanover, , Germany
MorphoSys Research Site
Heidelberg, , Germany
MorphoSys Research Site
Heilbronn, , Germany
MorphoSys Research Site
Landshut, , Germany
MorphoSys Research Site
Lebach, , Germany
MorphoSys Research Site
Lübeck, , Germany
MorphoSys Research Site
Mainz, , Germany
MorphoSys Research Site
Münster, , Germany
MorphoSys Research Site
Neustadt, , Germany
MorphoSys Research Site
Oldenburg, , Germany
MorphoSys Research Site
Oldenburg in Holstein, , Germany
MorphoSys Research Site
Potsdam, , Germany
MorphoSys Research Site
Ratingen, , Germany
MorphoSys Research Site
Saarbrücken, , Germany
MorphoSys Research Site
Schorndorf, , Germany
MorphoSys Research Site
Stuttgart, , Germany
MorphoSys Research Site
Villingen-Schwenningen, , Germany
MorphoSys Research Site
Wilhelmshaven, , Germany
MorphoSys Research Site
Wolfsburg, , Germany
MorphoSys Research Site
Alessandria, , Italy
MorphoSys Research Site
Ancona, , Italy
MorphoSys Research Site
Aviano, , Italy
MorphoSys Research Site
Bergamo, , Italy
MorphoSys Research Site
Bologna, , Italy
MorphoSys Research Site
Como, , Italy
MorphoSys Research Site
Cremona, , Italy
MorphoSys Research Site
Florence, , Italy
MorphoSys Research Site
Lecce, , Italy
MorphoSys Research Site
Milan, , Italy
MorphoSys Research Site
Modena, , Italy
MorphoSys Research Site
Napoli, , Italy
MorphoSys Research Site
Palermo, , Italy
MorphoSys Research Site
Perugia, , Italy
MorphoSys Research Site
Piacenza, , Italy
MorphoSys Research Site
Ponderano, , Italy
MorphoSys Research Site
Ravenna, , Italy
MorphoSys Research Site
Reggio Calabria, , Italy
MorphoSys Research Site
Rimini, , Italy
MorphoSys Research Site
Roma, , Italy
MorphoSys Research Site
Roma, , Italy
MorphoSys Research Site
Roma, , Italy
MorphoSys Research Site
Terni, , Italy
MorphoSys Research Site
Udine, , Italy
MorphoSys Research Site
Vicenza, , Italy
MorphoSys Research Site
Busan, , South Korea
MorphoSys Research Site
Busan, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Ulsan, , South Korea
MorphoSys Research Site
Badalona, , Spain
MorphoSys Research Site
Barcelona, , Spain
MorphoSys Research Site
L'Hospitalet de Llobregat, , Spain
MorphoSys Research Site
Lugo, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Majadahonda, , Spain
MorphoSys Research Site
Palma de Mallorca, , Spain
MorphoSys Research Site
Palma de Mallorca, , Spain
MorphoSys Research Site
Pamplona, , Spain
MorphoSys Research Site
Pozuelo de Alarcón, , Spain
MorphoSys Research Site
Sabadell, , Spain
MorphoSys Research Site
Salamanca, , Spain
MorphoSys Research Site
Santander, , Spain
MorphoSys Research Site
Seville, , Spain
MorphoSys Research Site
Valencia, , Spain
MorphoSys Research Site
Valencia, , Spain
MorphoSys Research Site
Valladolid, , Spain
MorphoSys Research Site
Valladolid, , Spain
MorphoSys Research Site
Taichung, , Taiwan
MorphoSys Research Site
Tainan City, , Taiwan
MorphoSys Research Site
Taipei, , Taiwan
MorphoSys Research Site
Brighton, , United Kingdom
MorphoSys Research Site
Manchester, , United Kingdom
MorphoSys Research Site
Sunderland, , United Kingdom
MorphoSys Research Site
Taunton, , United Kingdom
MorphoSys Research Site
Truro, , United Kingdom
MorphoSys Research Site
Westcliff-on-Sea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12.
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOR208C213
Identifier Type: -
Identifier Source: org_study_id